Last reviewed · How we verify

NCT03925298

Troponin- I Elevation Predicts Outcome After Thrombolysis in Stroke Patients

Completed Last updated 24 April 2019
What this trial tests

trial in Cerebrovascular Accident in 81 participants. Completed in 31 March 2019.

Timeline
1 January 2017
Primary endpoint
31 January 2019
31 March 2019

Quick facts

Lead sponsorZagazig University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment81
Start date1 January 2017
Primary completion31 January 2019
Estimated completion31 March 2019

Conditions studied

Sponsor

Zagazig University

Who can join

Eligibility, any sex, with Cerebrovascular Accident. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Elevated level of serum troponin (T-I) has been regarded as a prognostic biomarker of poor outcome in acute ischemic stroke. However, its role in outcome in thrombolysed ischemic stroke patients remains uncertain. The aim of this study was to evaluate the role of T-I as a predictive biomarker of short-term outcome in thrombolysed ischemic stroke participants.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Cerebrovascular Accident

Currently open trials in the same condition.

Other Zagazig University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03925298.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing